Bantam Pharmaceutical

bantam pharmaceutical is a privately held biopharmaceutical company focused on the discovery and development of novel small molecule cancer therapeutics that are effective in kras positive solid tumors. bantam’s candidate drug is selectively active against a diverse group of kras positive solid tumors and hematological malignancies. our candidate drug exhibits no activity against normal cells, limited biochemical activity against a broad array of molecular targets, excellent pharmacokinetics, and there are no observed toxicities to date. notably, pre-clinical in vivo proof of concept studies have demonstrated sustained tumor regression or growth inhibition in b-cell lymphoma and kras mutant colorectal cancer models. the company’s current early phase clinical trajectory is directed toward niches of unmet clinical need in relapsed/refractory kras mutant colorectal cancers. in addition, we are proceeding other select indications (e.g. other kras mutant cancers and diffuse large b-cell lym